Microsoft and Bristol Myers Squibb have partnered to improve early detection of lung cancer using AI-powered radiology tools.
Key Details
- 1The collaboration aims to leverage Microsoft's scalable AI imaging platform and BMS’s oncology expertise.
- 2Focus is on optimizing early detection and care pathways for non-small cell lung cancer patients.
- 3Targeted initiatives include addressing low adherence to follow-up and improving workflows for underserved populations.
- 4Lung cancer claims about 125,000 U.S. lives annually, but early diagnosis via low-dose CT reduces mortality risk.
- 5The partnership seeks to deliver scalable diagnostic tools and efficiency gains for healthcare organizations.
Why It Matters
Early lung cancer detection has a clear impact on patient survival, but screening adherence remains low. Integrating scalable AI radiology platforms with oncology expertise could significantly improve workflows, diagnosis, and patient outcomes, especially for underserved populations.
Source
Radiology Business
Related News
•Radiology Business
SimonMed Imaging Introduces Paid AI Add-Ons for Routine Exams
SimonMed Imaging is launching new AI-powered elective services for routine imaging exams with additional out-of-pocket costs for patients.
•Radiology Business
Aidoc Raises $150M to Expand Imaging AI Portfolio and Global Reach
Aidoc secures $150M in Series E funding led by Goldman Sachs to accelerate expansion of its clinical AI platform.
•Radiology Business
AI Model Outperforms Radiologists in Early Pancreatic Cancer Detection
REMOD, a new AI model, detects pancreatic cancer on CT scans much earlier and more accurately than radiologists.